Oral dexamethasone attenuates Doxil®-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies
Authors:
- David S MillerDavid S Miller
- Robert L ColemanRCRobert L Coleman
- 1 August 2004
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 94 (2) , 320-324
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Liposomal Doxorubicin in Ovarian, Peritoneal, and Tubal Carcinoma: A Retrospective Comparative Study of Single-Agent DosagesGynecologic Oncology, 2001
- Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus TopotecanJournal of Clinical Oncology, 2001
- Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinomaCancer, 2000
- Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesiaCancer Chemotherapy and Pharmacology, 1999
- Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.Journal of Clinical Oncology, 1997
- Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.Journal of Clinical Oncology, 1995
- Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in ChildhoodNew England Journal of Medicine, 1991
- Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusionInvestigational New Drugs, 1990
- Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.Proceedings of the National Academy of Sciences, 1988
- AdriamycinAnnals of Internal Medicine, 1974